ClinicalTrials.gg
CompletedNCT03276988Updated Sep 9, 2020

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

A Phase 1/2 interventional study of Period 1 GX-30, Period 2 THYROGEN® and Period 1 THYROGEN®, Period 2 GX-30 in Total Thyroidectomy and Near-total Thyroidectomy, sponsored by Genexine, Inc.. Completed at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Genexine, Inc. · Phase 1/2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Thyrotropin Alfa · Thyroid Neoplasms.

Enrollment
10th of 11
8 · median 63
Started
2017
the only one that year
Phase 1/2
2 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Genexine, Inc.

Among the 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1/2, and was the 6th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

1 of the 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Thyrotropin Alfa

Thyrotropin Alfa: first FDA approval 1998 (THYROGEN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Thyrotropin Alfa in Thyroid Neoplasms, or all of them as a file.
02

Study summary

This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total thyroidectomy of GX-30 and it has been completed. The Part B is currently recruiting and will investigate the efficacy and safety of GX-30 compared with THYROGEN®.

Read the detailed description

Recombinant human TSH was developed to provide TSH stimulation without withdrawal of thyroid hormone. Radioiodine ablation and diagnosis with rhTSH became the standard of care treatment for patients with differentiated thyroid cancer. Stably supplying rhTSH has been the unmet need for management and follow-up procedure for thyroid remnant. GX-30 is an investigational product, developed to provide inexpensive rhTSH to patients in order to ensure stable supply of rhTSH.

03

Conditions studied

  • Total Thyroidectomy
  • Near-total Thyroidectomy

Browse trials for

Keywords

  • Thyroid cancer
  • Thyroidectomy
  • rhTSH
  • GX-30
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who voluntarily consented, after listing enough explanation for this study and product.
  • Minimum 19 years old.
  • Minimum 50kg of body weight.
  • Patients who had undergone total thyroidectomy or near total thyroidectomy due to differentiated thyroid carcinoma.
  • Patient undergoing thyroid hormone administration.

Exclusion criteria

Exclusion Criteria:

  • Thyroid cancer excluding differentiated thyroid carcinoma.
  • Thyroidectomy excluding total thyroidectomy and near total thyroidectomy.
  • Patients with heart, renal, or liver failure.
  • Patients with ischemic stroke or the history of ischemic stroke.
  • Smoker or Ex-smoker with less than 3 months of stopping
  • Patients with migraine or the history of migraine.
  • Patients that the researchers do not think fit into the group, including patients failed in compliance assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Other
    Part B - Sequence A

    Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection

    Drug: Period 1 GX-30, Period 2 THYROGEN®

  • Other
    Part B - Sequence B

    Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection

    Drug: Period 1 THYROGEN®, Period 2 GX-30

Interventions

  • DrugThyrotropin AlfaStudies of Thyrotropin AlfaThyrotropin Alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.

    Also known as: Thyrotropin alpha

  • DrugThyrotropin AlfaStudies of Thyrotropin AlfaThyrotropin Alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.

    Also known as: Thyrotropin alpha

06

What researchers measure

Primary outcomes

  1. Efficacy (Part B)

    I-123 Whole body scan image classification

    Time frame: at each Day 4, period 1 and period 2.

Secondary outcomes

  1. TSH concentration (Part B)

    TSH concentration for Pharmacokinetics assessment

    Time frame: Baseline, Day 1 to Day 8.

  2. ADA (Part B)

    Anti-Drug Antibody detection

    Time frame: Baseline, Day 1 and 15 of Period 2

  3. Tg concentration (Part B)

    Thyroglobulin concentration for secondary efficacy assessment

    Time frame: Baseline, Day 1 to Day 5

  4. T3, free T4 concentration (Part B)

    Thyroid hormones concentration for pharmacodynamic assessment

    Time frame: Baseline, Day 1, 2, 5 of each period and Day 15 of period 2.

  5. Adverse events (Part B)

    Safety assessment

    Time frame: through study completion, average of 6 weeks.

07

Study locations

5 sites
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Ajou University Hospital
    Suwon, 16499, Korea, Republic of
08

References and documents

Publications

  • Goel R, Raju R, Maharudraiah J, Sameer Kumar GS, Ghosh K, Kumar A, Lakshmi TP, Sharma J, Sharma R, Balakrishnan L, Pan A, Kandasamy K, Christopher R, Krishna V, Mohan SS, Harsha HC, Mathur PP, Pandey A, Keshava Prasad TS. A Signaling Network of Thyroid-Stimulating Hormone. J Proteomics Bioinform. 2011 Oct 29;4:10.4172/jpb.1000195. doi: 10.4172/jpb.1000195. PubMed 24255551 ↗
  • Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994 Jan;78(1):188-96. doi: 10.1210/jcem.78.1.8288703. PubMed 8288703 ↗
  • Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab. 2001 Apr;86(4):1660-4. doi: 10.1210/jcem.86.4.7405. PubMed 11297600 ↗
  • Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997 Sep 25;337(13):888-96. doi: 10.1056/NEJM199709253371304. PubMed 9302303 ↗
  • Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov;84(11):3877-85. doi: 10.1210/jcem.84.11.6094. PubMed 10566623 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jan 2020, 28 months.

Of 21 phase 1/2 interventional studies under Thyroid Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2017
First posted
Sep 8, 2017
StartActual
Sep 7, 2017
Primary completionActual
Jan 20, 2020
CompletionActual
Jan 20, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03276988
Lead sponsor
Genexine, Inc.
Collaborators
Symyoo
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Sep 7, 2017
Primary completion
Jan 20, 2020
Completion
Jan 20, 2020
Last update
Sep 9, 2020

Study contacts

Mu Il Kang, M.D., Ph. D.
principal investigator · Seoul St. Mary's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thyrotropin Alfa

Start the discussion